慢性非细菌性前列腺炎的综合治疗

目的探讨应用综合治疗法治疗慢性非细菌性前列腺炎的临床疗效及安全性。方法1524例慢性非细菌性前列腺炎患者，分成3组：综合治疗组（心理治疗、前列腺按摩、植物类药和α受体阻滞剂等治疗相结合）、西医治疗组（α受体阻滞剂＋抗生素）以及中药治疗组，分别随访8周，并对各组疗效和症状改善程度进行分析评估。结果综合治疗组总有效率为83．2％，西医治疗组为35．5％，中药治疗组为41．3％，综合治疗组与两对照组之间P值均小于0．01，有显著的统计学差异。结论应用综合疗法治疗慢性非细菌性前列腺炎临床效果满意、安全性可靠。     

综合治疗慢性非细菌性前列腺炎

目的探讨综合治疗法治疗慢性非细菌性前列腺炎的临床疗效。方法346例慢性非细菌性前列腺炎患者,随机分成两组：综合治疗组188例（高频电容场治疗＋心理治疗＋前列腺按摩＋α-受体阻滞剂等）,对照组158例（α-受体阻滞剂＋抗生素）,分别治疗6～8周,并随访6～8周,对两组疗效和症状改善程度进行评估。结果治疗6～8周,综合治疗组总有效率为93．6％,对照组为48．1％,综合治疗组与对照组之间有统计学意义（P〈0．01）。结论应用综合疗法治疗慢性非细菌性前列腺炎临床效果满意,优于单纯药物治疗。     

慢性细菌性前列腺炎的联合治疗

目的 探讨慢性细菌性前列腺炎治疗的有效方法。方法 对65例患者分组采用联合治疗、个体化治疗的方法和单用抗生素治疗方法对比治疗，观察其各组疗效。结果 治疗组的治愈率为66．67％；总有效率为93．94％。而对照组的治愈率为31．257％；总有效率为71．87％。结论 联合治疗、个体化治疗要比单纯抗生素治疗慢性细菌性前列腺炎的疗效确切。     

规律射精治疗慢性非细菌性前列腺炎48例临床研究

慢性非细菌性前列腺炎（CAP）是中青年常见病，其病因尚不明确，临床表现复杂多样，治疗方法也不统。患者虽经长期治疗，但效果不佳。我们采用前瞻性对比法对48例CAP患者规律射精前后前列腺炎主客观症状变化进行观察，探讨规律射精在治疗CAP中的作用。     

舍尼通治疗慢性非细菌性前列腺炎的临床研究

目的 评价舍尼通(Prostat)治疗慢性非细菌性前列腺炎(CNP)的有效性及安全性。方法 采用多中心开放临床试验方法，对115例慢性非细菌性前列腺炎患者进行为期8周的观察。口服舍尼通每天2次，每次1片(含70mg水溶性提取物P5及4mg脂溶性提取物EAl0)。结果 治疗后4周和8周，患者国际慢性前列腺炎症状评分(NIH-CPSI)总分分别较治疗前平均降低7．1(29．5％)和11．9(49．4％)，症状尺度评分分别较治疗前平均降低5．0(32．1％)和8．2(52．5％)，生活质量评分分别较治疗前平均降低2．1(24．6％)和3．7(43．9％)，前列腺液中WBC计数分别较治疗前平均降低8．8个／HP(39．3％)和13．9个／HP(61．9％)。治疗8周后总有效率82．1％。全组病例观察过程中未发现任何与药物有关的不良反应。结论 舍尼通可明显改善慢性非细菌性前列腺炎患者的疼痛不适症状和排尿症状，改善生活质量，减少前列腺液中的WBC计数，治疗效果确切，耐受性良好。     

锌硒宝片治疗慢性细菌性前列腺炎的临床研究

慢性细菌性前列性炎(CBP)是成年男性常见病。文献报道认为前列腺液中有抗菌作用的活性蛋白,其主要活性成分为锌。Mamer等认为,只要能提高前列腺Zn浓度,便可治疗CBP。我们观察了一组病人用锌制剂治疗CBP,现报道如下。     

疏肝理气法治疗慢性非细菌性前列腺炎的临床研究

目的 :评价疏肝理气法治疗慢性非细菌性前列腺炎的疗效。　方法 :选用慢性非细菌性前列腺炎病人 6 0例 ,随机分成疏肝理气法治疗组 (n =31)和活血化瘀对照组 (n =2 9)。　结果 :疏肝理气法组总显效率为 83.86 % ,总有效率为 93.5 5 % ,活血化瘀组总显效率为 6 5 .5 2 % ,总有效率为 93.10 %。且治疗组在降低NIH CPSI积分、改善疼痛或不适及排尿症状、提高病人生活质量方面明显优于活血化瘀组。　结论 :疏肝理气法是治疗慢性非细菌性前列腺炎有效方法     

中西医结合治疗慢性细菌性前列腺炎

慢性细菌性前列腺炎是泌尿外科常见却又非常棘手的一种感染性疾病，由于抗菌药物难以通过前列腺包膜，治疗效果极差。我科自1995年1月－1999年12月中西医结合治疗146例，旨在通过中药清利益肾化瘀，改善前列腺局部药物弥散浓度，使治疗效果明显提高，现报告如下。     

多沙唑嗪有效治疗慢性非细菌性前列腺炎

Evliyaoglu Y等进行的一项研究中,通过与安慰剂比较,评价了多沙唑嗪单一疗法治疗慢性前列腺炎的疗效。评估指标有尿路症状、疼痛和生活质量。入选了60例慢性前列腺炎男性患者,并随机分为两组,一组每     

可乐必妥治疗慢性细菌性前列腺炎60例

前列腺炎是成年男性常见病,30岁以上男性发病率为35％～40％、1998-01～2001-05我们用第一制药(中国)有限公司生产的可乐必妥片剂治疗慢性细菌性前列腺炎(CBP)60例,疗效较好,报告如下。     

Eradication of Chlamydia trachomatis parallels symptom regression in chronic bacterial prostatitis patients treated with a fluoroquinolone-macrolide combination

To investigate the association between eradication of Chlamydia trachomatis (CT) and symptom regression in chronic prostatitis, 55 symptomatic patients were subjected to segmented tests to localise CT in first voided urine (VB1), prostatic secretions (EPS), post-massage voided (VB3) or semen specimens. Patients were divided in three treatment groups: the 'urethral involvement' group ('U': VB1 positive, EPS/VB3/Semen negative) was treated with 500 mg day(-1) azithromycin for 3 days. The 'prostatitis' group ('P': VB1 negative, EPS/VB3/semen positive) with 4-week levofloxacin-azithromycin combination. A third group, 'U+P' (VB1, EPS/VB3/semen positive) received both treatments in sequence. In P patients, eradication of CT was paralleled by marked, sustained symptom improvement and by significant decrease of serum prostate-specific antigen (PSA) levels. Compared with U patients, undergoing rapid regression of symptoms related to painful micturition after short-term azithromycin, U+P patients showed symptom and pathogen persistence in VB3/EPS/semen and required additional treatment with 4-week levofloxacin-azithromycin to achieve pathogen eradication, symptom regression, and decrease of PSA. Our results support a causative role of CT in chronic bacterial prostatitis. In the presence of a positive urethral localisation of the pathogen, thorough microbiological investigation together with focused symptom analysis may reveal an underlying chlamydial prostatitis and direct effective therapy with appropriate antibacterial agents.     

中西医结合综合治疗慢性前列腺炎2 284例分析

目的　评估中西医结合综合治疗慢性前列腺炎的临床效果。方法　 2 2 84例慢性前列腺炎患者 ,分成三组 :中西医结合治疗组 (心理行为治疗、前列腺按摩、消炎冲剂和抗生素等治疗相结合 )、抗生素对照组以及中药对照组 ,随访 4～ 8周 ,并对各组疗效进行分析评估。结果　中西医结合组总有效率为 84.8% ,抗生素对照组为3 4.2 % ,中药对照组为 41%。中西医结合组与两对照组之间P值均小于 0 .0 5 ,有显著的统计学差异。结论　运用中西医结合的方法综合治疗慢性前列腺炎临床效果满意     

慢性细菌性前列腺炎模型兔的尿流动力学研究

目的观察兔慢性细菌性前列腺炎(CBP)的尿流动力学变化。方法选用健康雄性大白兔，依文献方法，通过后尿道反复灌注大肠埃希菌制备CBP动物模型：模型成功后进行尿流动力学测定。结果与正常组相比，模型组主要表现为最大逼尿肌压、最大尿道压明显升高，而膀胱容量及顺应性无明显改变。结论兔慢性细菌性前列腺炎尿流动力学指标具有一定程度的异常改变，并可能与其发病机制密切相关。     

三种方法治疗慢性细菌性前列腺炎的病理变化

目的：治疗慢性细菌性前列腺炎(CBP)的有效方法和给药途径。方法：将雄性大白兔45只中的40只制备成CBP动物模型，分别口服氧氟沙星，口服氧氟沙星和特拉唑嗪，前列腺内注射氧氟沙星加地塞米松治疗，并以正常前列腺、CBP不用药及注射生理盐水者作为对照，光镜下观察前列腺组织的病理学改变。结果：三种用药方法均可有效减轻CBP的组织炎症情况。结论：前列腺内药物注射治疗CBP并无疗效优势。     

心理干预疗法在治疗慢性前列腺炎中的应用

目的观察心理干预疗法联合药物治疗慢性前列腺炎（CP）的临床效果,探讨慢性前列腺炎的心理治疗问题。方珐将192例CP患者随机分为两组,对照组96例,采用临床常规方法进行治疗;治疗组96例,在接受临床常规治疗的同时应用心理干预疗法。疗程2个月。治疗前后两组分别应用国际慢性前列腺炎症状评分（NIH—CPSI）测评症状严重程度,国际勃起功能指数-5（IIEF-5）测评患者性功能状况,焦虑自评量表（SAS）、抑郁自评量表（SDS）测评患者焦虑、抑郁等情绪障碍的患病状况。各项结果进行统计学分析。结果治疗后两组患者前列腺炎症状和性功能障碍均有改善,但治疗组改善程度明显优于对照组（P〈0．05）。对照组治疗后SAS、SDS评分无显著性差异（P〉0．05）;而治疗组治疗后SAS、SDS评分有显著性差异（P〈0．005）。结论心理干预可有效改善慢性前列腺炎患者的心理状态和性功能状况。对于CP患者在进行常规治疗的同时应积极应用心理干预治疗。     

Safety and efficacy of levofloxacin versus ciprofloxacin for the treatment of chronic bacterial prostatitis in Chinese patients

Levofloxacin is a synthetic fluoroquinolone that is usually used to treat chronic bacterial prostatitis. We investigated the safety and efficacy of levofloxacin compared with ciprofloxacin for the treatment of chronic bacterial prostatitis in Chinese patients. This was a multicenter, open-label, randomized controlled non-inferiority trial. Four hundred and seventy-one patients with clinical symptoms/signs were enrolled into the study, and 408 patients were microbiologically confirmed chronic bacterial prostatitis, who were randomized to either oral levofloxacin (500 mg q.d.) or ciprofloxacin (500 mg b.i.d.) for 4 weeks. Bacterial clearance rate, clinical symptoms/signs, adverse reactions and disease recurrence were assessed. The clinical symptoms and signs (including dysuria, perineal discomfort or pain) and bacteria cultures in 209 patients treated with levofloxacin and 199 patients treated with ciprofloxacin were similar. The most common bacteria were Escherichia coli and Staphylococcus aureus. One to four weeks after the end of 4 weeks treatment, the bacterial clearance rate (86.06% vs. 60.03% P<0.05) and the clinical efficacy (including clinical cure and clinical improvement(93.30% vs. 71.86% P<0.05)) were significantly higher in the levofloxacin-treated group than in the ciprofloxacin-treated group. The microbiological recurrence rate was significantly lower in the levofloxacin-treated group than in the ciprofloxacin-treated group (4.00% vs. 19.25% P<0.05). Rates of adverse events and treatment-related adverse events were slightly lower in the levofloxacin-treated group than in ciprofloxacin-treated group. Levofloxacin showed some advantages over ciprofloxacin in terms of clinical efficacy and disease recurrence, with a low rate of adverse events, for the treatment of chronic bacterial prostatitis in Chinese patients.     

Clinical classification of chronic prostatitis： a preliminary investigation

Aim: To propose a practical clinical classification for the chronic prostatitis (CP). Methods: The clinical fea-tures and the findings in the expressed prostatic secretion (EPS) in 804 cases of CP patients were retrospectively ana-lyzed. Results: Four types of CP were identified based on the clinical manifestations and the amounts of whiteblood cells (WBC) and lecithin in EPS. They were the latent type (85 cases; 10.6%), the common type (423 cases;52.6%), the persisting type (104 cases; 12.9%), and the active type (192 cases, 23.9%). The therapeutic efficacyfor these 4 subtypes were 40.4%, 76.8%, 30.8% and 37%, respectively; a statistical difference was noticed be-tween the common type and the persisting type (P < 0.01 ). Conclusion: The method of classification proposed bythe authors may help clinicians in the diagnosis and predicting the prognosis of CP. (Asian J Androl 2000 Dec; 2:311-313)     

Effects of androgen deprivation on chronic bacterial prostatitis in a rat model

BACKGROUND: Many attempts have been made to improve the treatment success rate of chronic bacterial prostatitis (CBP). However, no treatment modality has achieved complete cure. The growth and development of the prostate is under direct hormonal control, and it is possible that prostatitis may be directly influenced by its hormonal milieu in a similar fashion to benign prostatic hyperplasia and prostate cancer. Therefore, the effects of androgen deprivation on the treatment of CBP were investigated in rats. METHODS: Experimental CBP was induced in one hundred, male Wistar rats by instillation of bacterial suspension (Escherichia coli Z17, O2: K1: H-) containing 1 x 10(8) CFU/ microL into the prostatic urethra. Microbiologically and histologically proven CBP was demonstrated in 62% (62 of 100) of the rats after 4 weeks of bacterial instillation. The 62 rats demonstrating CBP were randomly divided into five groups: control; castration; finasteride; estrogen; and levofloxacin groups. All drug treatments were conducted over a period of 4 weeks. RESULTS: Microbiological cultures and histological findings of the prostate and urine samples demonstrated reduced bacterial growth and improved inflammatory responses in all four experimental groups compared with the control group. The castration and estrogen groups showed coherent trends of decrease in bacterial growth and improvements in prostatic inflammation compared with the control group, but not to a statistically significant degree (P > 0.05). However, the finasteride and levofloxacin groups did show statistically significant decreases in bacterial growth and improvements in prostatic inflammation compared with the control group (P < 0.05). CONCLUSION: These results suggest that androgen deprivation is an effective modality in CBP treatment. In particular, the finasteride treatment reduced the severity of CBP in the animal model without reducing the systemic testosterone level. The combination of finasteride and levofloxacin maybe one of the effective treatment modalities for CBP.